v3.22.2.2
Statements of Operations (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 1,553,295 $ 799,779 $ 4,761,686 $ 2,347,564
General and administrative 892,777 912,490 3,201,111 2,956,444
Total operating expenses 2,446,072 1,712,269 7,962,797 5,304,008
Loss from operations (2,446,072) (1,712,269) (7,962,797) (5,304,008)
Other income and expenses:        
Interest (income) expense, net (21,486) 651 (21,486) 45,613
Net loss (2,424,586) (1,712,920) (7,941,311) (5,349,621)
Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6) 0 269,038 0 269,038
Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6) 0 2,293,199 0 2,293,199
Net loss attributable to common stockholders $ (2,424,586) $ (4,275,157) $ (7,941,311) $ (7,911,858)
Net loss per share of common stock, basic and diluted $ (0.20) $ (0.86) $ (0.75) $ (2.69)
Weighted-average basic and diluted common units/shares 12,276,394 4,980,306 10,622,277 2,945,351

Source